Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

¹Dokuz Eylül Üniversitesi Tıp Fakültesi, Göz Hastalıkları A.D., İzmir, Asist. Dr.
²Dokuz Eylül Üniversitesi Tıp Fakültesi, Göz Hastalıkları A.D., İzmir, Doç. Dr.
³Dokuz Eylül Üniversitesi Tıp Fakültesi, Göz Hastalıkları A.D., İzmir, Prof. Dr. Purpose: To evaluate the efficacy of intravitreal pegaptanib sodium injection in the treatment of wet type age-related macular degeneration (AMD).
Materials and Methods: 52 eyes from 52 patients treated for wet type AMD were evaluated retrospectively at the Retina unit of Dokuz Eylul University Ophthalmology Department. All subtypes of wet type AMD were included. Pre and post injection visual acuities, number of pegaptanib injections, additional treatment modalities and follow up period were assessed.
Results: Twenty three patients were female and 29 were male. Mean age was 71.4±10.5 years. Fourtysix% (24/52) of the lesions were predominantly classic, 28.8% (15/52) occult and 25% (13/52) pigment epithelial detachment. The mean follow up was 6.2±3.1 months. The average number of pegaptanib injections was 2.0 (1-5). During the follow up, intravitreal bevacizumab was adminstrated in 10 patients, intravitreal triamcinolon injection was given to 7 patients and a single photodynamic treatment (PDT) was performed in 15 patients and two PDT sessions were given to one patient. Mean visual acuity was 0.97±0.3 logMAR unit at initial examination and 0.96±0.3 logMAR unit at the end of follow up. There was no statistically significant difference between the visual acuities (p>0.05). No serious complications were observed after the pegaptanib injections.
Conclusion: Intravitreal injection of pegaptanib sodium resulted in visual acuity stabilisation in our group of patients. Intravitreal injection of pegaptanib Na is a safe alternative in wet-type AMD. Keywords : Age-related macular degeneration, Macula, Pegaptanib, vascular endothelial growth factor